Data are available from the Korean National Health Insurance Corporation (<https://nhiss.nhis.or.kr/bd/ab/bdaba002cv.do>) for researchers who meet the criteria for access to confidential data. These are third party data. We did not have any special access privileges that others would not have. Anyone can submit a research proposal online (<https://nhiss.nhis.or.kr/bd/ab/bdaba021eng.do>). If the proposal is accepted by an evaluation committee of NHIC, the researcher would receive the de-identified NHIC dataset after paying some fee.

Introduction {#sec005}
============

Prostate cancer (PCa) is the second most commonly diagnosed cancer and the sixth most common cause of cancer-related mortality among men worldwide \[[@pone.0201308.ref001]\]. Although localized PCa usually has a good prognosis, prostatectomy often results in complications, such as erectile dysfunction or urinary incontinence that dramatically deteriorate~~s~~ the quality of life \[[@pone.0201308.ref002]\]. Nonetheless, the only established risk factors for PCa are age, race, and family history \[[@pone.0201308.ref003]\]. Regarding race, Asian men have a far lower incidence of PCa than those in Western countries, and the large geographic disparity in the incidence implies that lifestyle factors may contribute to the etiology of the disease \[[@pone.0201308.ref003]\].

Nonalcoholic fatty liver disease (NAFLD), which has become one of the main liver diseases worldwide \[[@pone.0201308.ref004]\], is closely associated with insulin resistance and metabolic syndrome. The hepatic accumulation of triacylglycerol is accompanied by abnormal hepatic metabolism and impaired insulin-mediated suppression of hepatic glucose leading to hyperglycemia, hypertriglydemia, and hyperinsulinemia \[[@pone.0201308.ref005]\]. Recently, the association between NAFLD and PCa has been postulated by increasing occurrences of both PCa and NAFLD, suggesting that westernization is an important risk factor for PCa \[[@pone.0201308.ref006]\].

There has been growing evidence~~s~~ that supports the hypothesis that metabolic syndrome is involved in the development and progression of certain types of malignancies \[[@pone.0201308.ref007]\], including PCa \[[@pone.0201308.ref008]\]. Given that the close association between metabolic syndrome and NAFLD, NAFLD can share common risk factors for PCa. The association of NAFLD with other extra-hepatic cancers is less proven compared with metabolic syndrome \[[@pone.0201308.ref009]\]. Concerning PCa, only two studies have evaluated the relationship between NAFLD and the development of PCa \[[@pone.0201308.ref010], [@pone.0201308.ref011]\].

On the grounds of this background, this study aimed to evaluate whether the NAFLD is associated with the development of PCa using nationwide data in Korea, where the incidence of both diseases is rapidly growing \[[@pone.0201308.ref012]\].

Materials and methods {#sec006}
=====================

Data source and study population {#sec007}
--------------------------------

We used the database of the National Health Insurance Corporation (NHIC), which is a national insurer managed by the Korean government and to which approximately 97% of the Korean population subscribes \[[@pone.0201308.ref013]\]. The NHIC recommended subscribers to undergo a standardized medical examination at least biennially. Any researcher can use the NHIC database if the official review committee approves the study protocols.

A diagnosis of PCa was defined using the International Classification of Diseases, 10th revision (ICD-10) codes (C61) and reimbursement code for severe disease.

Among 23,503,802 individuals who had undergone an annual or biennial evaluation provided by the NHIC between the years, 2009 and 2012, 11,649,836 female subjects were excluded. Then, the study population was restricted to 11,853,966 male subjects. Those aged less than 20 years or older than 85 years and those diagnosed as having liver cirrhosis (K703) or any hepatitis (K746), and heavy alcohol consumers (≥ 30 g of alcohol per occasion in men) were excluded. After excluding 20,990 subjects who had been diagnosed as having PCa or other malignancy before 2009, 10,516,985 subjects were finally analyzed. A summary of the study population selection is illustrated in [Fig 1](#pone.0201308.g001){ref-type="fig"}.

![Flowchart showing the enrolment process for the study cohort.\
NHIC, National Health Insurance Corporation.](pone.0201308.g001){#pone.0201308.g001}

Measurements of clinical parameters and biochemical analysis {#sec008}
------------------------------------------------------------

Standardized self-reporting questionnaires were used to collect data at the time of enrollment for the following variables, which are regarded as risk factors for liver injury and were included as covariates in multivariable analyses: age (years), sex, residence (rural and urban), yearly income (lower quintile vs. the remaining quintiles), alcohol intake (The frequency of alcohol consumption in 1 week and the amount of alcohol consumed on one occasion were evaluated (frequency: 0--7 days/week and amount: drinks per occasion), and cigarette smoking (never, former, and current). Regular exercise was defined as engaging in vigorous exercise on a regular basis (≥ high intensity of activity ≥ 3/week or moderate intensity of activity ≥ 5/week) \[[@pone.0201308.ref014]\]. Body mass index (BMI) and systolic and diastolic blood pressure (mmHg) were also measured. Subjects were considered obese when the BMI was ≥ 25 kg/m^2^ based on the criteria of the Asian-Pacific region \[[@pone.0201308.ref015]\]. Waist circumference ≥ 90 cm in men was defined as abdominal obesity \[[@pone.0201308.ref016]\]. Diabetes mellitus was defined based on using insulin or oral hypoglycemic agents, or a fasting plasma glucose level ≥ 126 mg/dL. Participants were diagnosed as being hypertensive if the systolic pressure was ≥ 140 mmHg, if the diastolic pressure was ≥ 90 mmHg, or if a current antihypertensive medication was used. After overnight fasting for at least 8 hours, blood specimens collected from each subject were processed and transported in cold storage to the Central Testing Institute (Neodin Medical Institute, Seoul, Korea). All the blood samples were analyzed within 24 hours after transportation. The serum levels of creatinine and the lipid and liver enzyme profiles were determined using a Hitachi 7600 automated chemistry analyzer (Hitachi, Tokyo, Japan) with specific indicated methods. Values of total cholesterol (mg/dL) and liver enzymes such as alanine transaminase (ALT), aspartate aminotransferase (AST), and γ-glutamyl transferase (GGT) in the serum (IU/L) were determined \[[@pone.0201308.ref017]\]. All procedures involving human participants were performed under the ethical standards of the institutional and national research committees, and 1964 Helsinki declaration including its later amendments or comparable ethical standards. Since the study involved routinely collected data, informed consent was not specifically obtained for this study. The study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (X-1608/360-906).

### Ethical approval {#sec009}

All procedures involving human participants were performed in accordance with the ethical standards of the institutional and national research committees, and the 1964 Helsinki declaration including its later amendments or comparable ethical standards. Informed consent for using information was exempted by the institutional and national research committees because this study used only previously collected data.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### Surrogate measure of fatty liver {#sec010}

Although ultrasonography is a first-line screening technique and the best proxy for the invasive liver biopsy, an only small portion of enrollees underwent this in NHIC. Therefore, noninvasive tests such as the fatty liver index (FLI) \[[@pone.0201308.ref018]\] or hepatic steatosis index (HSI) were used \[[@pone.0201308.ref019]\] with limited accuracy. The FLI, ranging from 0 to 100, was calculated according to an algorithm based on triglycerides levels, BMI, GGT, and waist circumference \[[@pone.0201308.ref020]\]: FLI = (e ^0.953×Ln(triglyceride)+0.139×BMI+0.718×Ln(GGT)+0.053×waist\ circumference--15.745^)/ (1+e ^0.953×Ln(triglyceride)+0.139×BMI+0.718×Ln(GGT)\ +0.053×waist\ circumference--15.745^)×100.

In this study, subjects were then categorized into three FLI groups: \< 30; 30 to 59 and ≥ 60 based on a previous studies \[[@pone.0201308.ref020], [@pone.0201308.ref021]\] Subjects were classified as having NAFLD if the FLI was ≥ 60 in the absence of other causes of chronic liver disease (e.g., a history of hepatitis or cirrhosis, hepatitis B surface antigen negative, and excessive alcohol consumption, as defined previously). As a supplementary criteria, the HSI = 8×(ALT/AST ratio) + BMI (+2, if female; +2, if diabetes mellitus) was calculated \[[@pone.0201308.ref019]\].

Statistical analyses {#sec011}
--------------------

Data are presented as the mean±standard deviation for normally distributed continuous variables and as proportions for categorical variables. The Student t test and analysis of variance were used to analyze continuous variables, and the differences between nominal variables were compared with the chi-square test. With regard to non-normally distributed variables, log transformations were performed. Among variables with a *P* value of less than 0.05 in univariate analyses, those with clinical importance were subjected to multivariate analyses. The incidence rates of cancers were calculated by dividing the number of events by person-time at risk. To determine the independent association of the FLI with the risk of cancer incidence, the Cox proportional hazards model was used after adjusting for age, smoking status, alcohol consumption, exercise, income, diabetes, hypertension and dyslipidemia. Subgroup analyses were performed according to age, smoking status, drinking habit, diabetes, metabolic syndrome components, obesity, abdominal obesity, physical activity, and yearly income.

Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R version 3.2.3 (The R Foundation for Statistical Computing, Vienna, Austria, <http://www.Rproject.org>). A two-sided *p* value less than 0.05 was considered statistically significant. The cut-off of *p* for interaction was 0.15.

Results {#sec012}
=======

Demographic characteristics {#sec013}
---------------------------

Of 10,516,985 Korean men included in the analysis, 50,284 (0.48%) developed PCa. The respective mean and median time to follow-up was 5.33 ± 1.16 years and 5.6 years (interquartile range \[IQR\]: 4.55--6.25). The geometric mean and median of the FLI value were 25.0 (95% CI 24.99--25.02) and 29.4 (IQR: 13.70--52.70). Those of HSI were 32.4 (95% CI 32.42--32.43) and 32.3 (IQR: 29.10--36.00). The prevalence rates of NAFLD based on the FLI and HSI were 19.0% and 25.0%, respectively. The total population was divided into two groups based on their FLI and HSI, respectively, and the baseline characteristics of the study participants are shown in ([Table 1](#pone.0201308.t001){ref-type="table"}). Clinical, anthropometric, and metabolic variables were analyzed according to the FLI and HSI grouping.

10.1371/journal.pone.0201308.t001

###### Demographics of the study enrollees.

![](pone.0201308.t001){#pone.0201308.t001g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                     Fatty liver index (FLI)   Hepatic steatosis index (HSI)                                                      
  ------------------------------------------------------------- ------------------------- ------------------------------- ---------- ------------------- ------------------- ---------
  Age (year)                                                    46.4 ± 14.5               46.5 ± 12.1                     \<0.001    47.1 ± 14.6         44.3 ± 12.2         \<0.001

  \< 40                                                         3,059,062 (35.9)          621,878(31.1)                              2663100 (33.8)      1,017,840 (38.7)    

  40, 65                                                        4,332,630 (50.9)          1,208,514(60.4)                            4,106,786 (52.1)    1434358 (54.5)      

  ≥ 65                                                          1,122,918 (13.2)          171,983(8.6)                               1,117,241 (14.2)    177,660 (6.8)       

  Current smoker                                                3,525,822 (41.4)          970,741(48.5)                   \<0.001    3,327,520 (42.2)    1,169,043 (44.5)    \<0.001

  Alcohol consumption[^a^](#t001fn003){ref-type="table-fn"}     5,208,303 (61.2)          1,428,035(71.3)                 \<0.001    4,999,483 (63.4)    1,636,855 (62.2)    \<0.001

  Exercise[^b^](#t001fn004){ref-type="table-fn"}                1,736,044 (20.4)          352,837(17.6)                   \<0.001    1,625,908 (20.6)    462,973 (17.6)      \<0.001

  Lower quintile of\                                            1,500,076 (17.6)          345,024(17.2)                   \<0.001    1,419,313 (18.0)    425,787 (16.2)      \<0.001
  yearly income                                                                                                                                                              

  BMI (Kg/m^2^)                                                 23.3 ± 2.5                27.6 ± 2.8                      \<0.001    23.1± 2.4           27.3 ± 2.7          \<0.001

  BMI ≥ 25 Kg/m^2^                                              2,184,407 (25.7)          1,676,258 (83.7)                \<0.001    1,696,006 (21.5)    2,164,659 (82.3)    \<0.001

  WC (cm)                                                       81.5±6.7                  92.2 ± 6.7                      \<0.001    81.3 ± 6.8          90.4 ± 7.0          \<0.001

  Abdominal obesity[^c^](#t001fn005){ref-type="table-fn"}       985418 (11.6)             1293758 (64.6)                  \<0.001    887,049 (11.3)      1,392,127 (52.9)    \<0.001

  SBP (mmHg)                                                    123.1±13.7                129.7 ± 14.2                    \<0.001    123.3 ± 14.0        127.5 ± 13.8        \<0.001

  DBP (mmHg)                                                    76.8±9.4                  81.6 ± 9.9                      \<0.001    76.9 ± 9.5          80.0 ± 9.7          \<0.001

  Diabetes                                                      734,276 (8.6)             357,436 (17.9)                  \<0.001    588,195 (7.5)       503,517(19.2)       \<0.001

  Hypertension                                                  2,007,695 (23.6)          850,134 (42.5)                  \<0.001    1,931,622 (24.5)    926,207 (35.2)      \<0.001

  Dyslipidemia[^d^](#t001fn006){ref-type="table-fn"}            1,211,270 (14.2)          658,228 (32.9)                  \<0.001    1,162,206 (14.7)    707,292 (26.9)      \<0.001

  ≥1 of metabolic\                                              2,930,397 (34.4)          1243657 (62.1)                  \<0.001    2,761,789 (35.0)    1,412,265 (53.7)    \<0.001
  syndrome component[^e^](#t001fn007){ref-type="table-fn"}                                                                                                                   

  Glucose (mg/dL)                                               97.3 ± 22.6               107.2 ± 31.5                    \<0.001    96.9 ± 21.9         105.9±31.2          \<0.001

  Cholesterol (mg/dL)                                           189.9 ± 34.5              209.9 ± 38.7                    \<0.001    190.6 ± 35.1        202.8±38.0          \<0.001

  Triglyceride (mg/dL) [^f^](#t001fn008){ref-type="table-fn"}   109.9\                    233.5\                          \<0.001    115.8\              166.4\              \<0.001
                                                                (109.9, 109.9)            (233.4, 233.7)                             (115.8, 115.9)      (166.3, 166.5)      

  AST (IU/L^)^[^f^](#t001fn008){ref-type="table-fn"}            23.2 (23.2, 23.2)         39.8 (39.7, 39.8)               \<0.001    21.8 (21.8, 21.8)   42.1 (42.0, 42.1)   \<0.001

  ALT (IU/L)[^f^](#t001fn008){ref-type="table-fn"}              24.4 (24.4, 24.4)         31.9 (31.9, 32.0)               \<0.001    24.7 (24.7, 24.7)   28.7 (28.7, 28.7)   \<0.001

  GGT (IU/L)[^f^](#t001fn008){ref-type="table-fn"}              29.36(29.4, 29.4)         71.8 (71.8, 71.9)               \<0.001    30.9 (30.8, 30.9)   50.0 (50.0, 50.0)   \<0.001

  Developing PCa                                                42,258 (0.5)              8,026 (0.4)                     \<0.001    41,162 (0.5)        9,122 (0.4)         \<0.001

  F/U duration (year)                                           5.4 ± 1.2                 5.3 ± 1.2                       \< 0.001   5.3 ± 1.2           5.3 ± 1.1           NS
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AST aspartate aminotransferase, ALT alanine transaminase, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FLI fatty liver index, F/U follow up, GGT gamma glutamyltransferase, HSI hepatic steatosis index, PCa prostate cancer, SD standard deviation, WC waist circumference, NS not significant.

Variables are expressed as mean ± SD or n (%).

^a^ Men who consumed alcohol ≥ 30g/day were initially excluded

^b^ Persons who did not perform high intensity of activity ≥ 3/week or moderate intensity of activity ≥ 5/week

^c^ Waist circumference ≥ 90cm for men

^d^ Triglyceride ≥ 150 mg/dL or user of lipid lowering drug

^e^ Having more than 1 of component among hypertension, dyslipidemia and diabetes mellitus

^f^ Geometric mean (95% confidence interval).

The FLI ≥ 60 group included more persons who smoked currently, consumed alcohol, and exercised less frequently. Moreover, subjects with an FLI ≥ 60 had higher blood pressure and higher values of fasting glucose, triglycerides, total cholesterol, AST, ALT, GGT, and BMI compared with those in the FLI\< 60 group. Regarding HSI, HSI≥ 36 group included more persons who smoked currently, exercised less frequently and had higher blood pressure and higher values of fasting glucose, triglyceride, total cholesterol, AST, ALT, GGT and BMI compared with those in the other group.

Among 2,002,375 men with FLI ≥ 60, 8,026 (0.4%) persons were diagnosed with PCa, while 42,258 (0.5%) persons developed PCa of 8,514,610 non-NAFLD individuals. The characteristics of these two groups according to the development of PCa were listed in [S1 Table](#pone.0201308.s001){ref-type="supplementary-material"}.

Multivariable analyses for risk factors associated with the development of PCa {#sec014}
------------------------------------------------------------------------------

Multivariate results of risks in developing PCa by FLI (or HSI) are shown in [Table 2](#pone.0201308.t002){ref-type="table"}. After adjusting for age, the HR for the development of PCa in the NAFLD group was higher than that in the other (model 1). After controlling for age, smoking, alcohol consumption, regular physical exercise, yearly income, DM, hypertension and dyslipidemia, FLI 30--60 and ≥ 60 were associated with an increased risk for PCa (model 2 and 3). When FLI groups were divided into \< 60 and ≥ 60, FLI ≥ 60 was still associated with an increased hazard ratio for PCa (model 4) (HR 1.05; 95% CI, 1.02--1.07). Regarding the HSI, a similar result was shown. That is, the higher the HSI, the higher the association with the risk for developing PCa ([Table 2](#pone.0201308.t002){ref-type="table"}).

10.1371/journal.pone.0201308.t002

###### Multivariable analyses of the impact of FLI and HSI on the risk of prostate cancer in the Korean population.

![](pone.0201308.t002){#pone.0201308.t002g}

  Group     N         Event   IR [^a^](#t002fn003){ref-type="table-fn"}   HR (95% CI)                                              
  --------- --------- ------- ------------------------------------------- ------------------ ------------------ ------------------ -------------------
  **FLI**                                                                                                                          
  \< 30     5338624   25209   0.88                                        1 \[Reference\]    1 \[Reference\]    1 \[Reference\]    1 \[Reference\]
  30--60    3175986   17049   1.00                                        1.13 (1.11,1.15)   1.12 (1.10,1.15)   1.10 (1.08,1.12)   
  ≥ 60      2002375   8026    0.76                                        1.14 (1.11,1.16)   1.14 (1.11,1.17)   1.09 (1.06,1.12)   1.05 (1.02, 1.07)
  **HSI**                                                                                                                          
  \< 30     3307795   17471   0.99                                        1 \[Reference\]    1 \[Reference\]    1 \[Reference\]    1 \[Reference\]
  30--36    4579184   23690   0.96                                        1.19 (1.17,1.21)   1.17 (1.15,1.20)   1.15 (1.13,1.18)   
  ≥ 36      2630006   9123    0.65                                        1.25 (1.21,1.28)   1.23 (1.20,1.26)   1.19 (1.16,1.23)   1.09 (1.06, 1.11)

CI confidential intervals, FLI fatty liver index, HSI hepatic steatosis index, HR hazard ratios,

IR incidence rate

^a^1,000 person, year

Model 1: Adjusted for age

Model 2: Adjusted for age, smoking, drinking, regular exercise, income

Model 3: Adjusted for age, smoking, drinking, regular exercise, income, diabetes, hypertension, and dyslipidemia

Model 4: FLI and HSI groups were divided into \< 60 and ≥ 60 or \< 36 and ≥36, respectively.

Adjusted for age, smoking, drinking, regular exercise, income, diabetes, hypertension, and dyslipidemia

### Effects of individual components of the FLI and HSI on the development of PCa {#sec015}

[Table 3](#pone.0201308.t003){ref-type="table"} shows the incidence rates and hazard ratios of PCa according to the BMI range, abdominal obesity, triglycerides level, and GGT and AST/ALT quartile that account for FLI or HSI. A BMI ≥ 23.0 kg/m^2^ increased the risk of PCa compared to a normal range of BMI, and there was a dose-dependent increase in the risk of PCa when the BMI increased (P ~trend~ \< 0.001). In contrast, underweight (BMI \< 18.5 kg/m^2^) showed a reduced risk of PCa (HR 0.77; 95% CI 0.72--0.81) after adjusting for age, smoking, alcohol consumption, exercise, and yearly income.

10.1371/journal.pone.0201308.t003

###### The impact of individual components of FLI and HSI scores on the risk for prostate cancer by multivariable analyses.

![](pone.0201308.t003){#pone.0201308.t003g}

  Variables                                                 Number    Outcome   Duration   IR     HR (95% CI)[^a^](#t003fn002){ref-type="table-fn"}   P trend
  --------------------------------------------------------- --------- --------- ---------- ------ --------------------------------------------------- ----------
  BMI                                                                                                                                                 \< 0.001
  \< 18.5 Kg/m^2^                                           252248    1249      1300796    0.96   0.77 (0.72, 0.81)                                   
  18.5, 23.0 Kg/m^2^                                        3580475   16757     19134023   0.88   1 \[Reference\]                                     
  23.0, 25.0 Kg/m^2^                                        2823597   14659     15165239   0.97   1.16 (1.14, 1.19)                                   
  25.0, 30.0 Kg/m^2^                                        3472109   16474     18521411   0.89   1.20 (1.17, 1.23)                                   
  ≥ 30.0 Kg/m^2^                                            388556    1145      2024372    0.57   1.26 (1.18, 1.33)                                   
  Abdominal obesity[^b^](#t003fn003){ref-type="table-fn"}                                         \< 0.001                                            
  No                                                        8237809   35575     44118188   0.81   1 \[Reference\]                                     
  Yes                                                       2279176   14709     12027653   1.22   1.15 (1.13, 1.17)                                   
  Dyslipidemia[^c^](#t003fn004){ref-type="table-fn"}                                                                                                  \< 0.001
  No                                                        6181691   28702     32986710   0.87   1 \[Reference\]                                     
  Yes                                                       4212159   21142     22438762   0.94   1.07 (1.06, 1.09)                                   
  Diabetes                                                                                                                                            \< 0.001
  No                                                        9425273   40424     50502501   0.80   1 \[Reference\]                                     
  yes                                                       1091712   9860      5643340    1.75   1.05 (1.03, 1.07)                                   
  GGT[^c^](#t003fn004){ref-type="table-fn"}                                                                                                           \< 0.001
  \< 21 IU/L                                                2600002   13157     13932884   0.94   1 \[Reference\]                                     
  \< 31 IU/L                                                2712295   14088     14590886   0.97   1.08 (1.05, 1.11)                                   
  \< 50 IU/L                                                2572446   12709     13779962   0.92   1.13 (1.10, 1.16)                                   
  ≥ 50 IU/L                                                 2632242   10330     13842109   0.75   1.08 (1.05, 1.11)                                   
  ALT/AST[^c^](#t003fn004){ref-type="table-fn"}                                                                                                       \< 0.001
  \< 0.8                                                    2643673   16950     13946366   1.22   1 \[Reference\]                                     
  0.8--1.0                                                  2463015   13489     13163352   1.02   1.10 (1.08, 1.13)                                   
  \< 1.3                                                    2781073   12479     14906255   0.84   1.16 (1.13, 1.19)                                   
  ≥ 1.3                                                     2629224   7366      14129868   0.52   1.14 (1.11, 1.17)                                   
  ALT[^d^](#t003fn005){ref-type="table-fn"}                                                                                                           \< 0.001
  \< 18 IU/L                                                2812374   15345     14900042   1.03   1 \[Reference\]                                     
  \< 24 IU/L                                                2535905   13787     13597829   1.01   1.08 (1.05, 1.10)                                   
  \< 34 IU/L                                                2552043   12282     13688390   0.90   1.11 (1.08, 1.14)                                   
  ≥ 34 IU/L                                                 2616663   8870      13959580   0.64   1.10 (1.07, 1.13)                                   
  AST[^d^](#t003fn005){ref-type="table-fn"}                                                                                                           0.236
  \< 20 IU/L                                                2526159   10557     13463044   0.78   1 \[Reference\]                                     
  \< 24 IU/L                                                2651440   12648     14213703   0.89   1.00 (0.97, 1.02)                                   
  \< 30 IU/L                                                2776167   14411     14891113   0.97   0.99 (0.96, 1.01)                                   
  ≥ 30 IU/L                                                 2563219   12668     13577982   0.93   0.99 (0.96, 1.01)                                   
  FLI[^d^](#t003fn005){ref-type="table-fn"}                                                                                                           \< 0.001
  \< 13.7                                                   2629246   10733     14039989   0.76   1 \[Reference\]                                     
  \< 29.4                                                   2629246   14011     14123644   0.99   1.16 (1.13, 1.19)                                   
  \< 52.7                                                   2629247   14370     14087052   1.02   1.22 (1.19, 1.25)                                   
  ≥ 52.7                                                    2629246   11170     13895157   0.80   1.24 (1.21, 1.27)                                   
  HSI[^d^](#t003fn005){ref-type="table-fn"}                                                                                                           \< 0.001
  \< 29.1                                                   2629307   13744     13942057   0.99   1 \[Reference\]                                     
  29.1--32.2                                                2629183   14142     14091688   1.00   1.18 (1.15, 1.21)                                   
  32.3--36.0                                                2629265   13279     14086812   0.94   1.24 (1.21, 1.27)                                   
  ≥ 36.0                                                    2629230   9119      14025284   0.65   1.27 (1.24, 1.31)                                   

AST aspartate aminotransferase, ALT alanine transaminase, BMI body mass index, GGT gamma glutamyltransferase, FLI fatty liver index, HSI hepatic steatosis index, IR incidence rate, WC waist circumference.

^a^ Adjusted by age, smoking, drinking, exercise and income

^b^ Waist circumference ≥ 90cm for men

^c^ Triglyceride ≥ 150 mg/dL or user of lipid-lowering drug

^d^ The value was divided into quartile

Abdominal obesity, high serum triglycerides levels, DM, GGT level ≥21 IU/mL, ALT level ≥18 IU/ml, and ALT/AST level ≥ 0.8 were associated with an increased risk of PCa, while the serum AST level was not. Finally, an FLI ≥13.7 and HSI ≥29.1 were associated with an increased risk of PCa, and dose-dependent increments were shown.

### Subgroup analyses according to age, smoking status, alcohol consumption, and metabolic health status {#sec016}

We performed subgroup analyses according to age, smoking status, alcohol consumption, DM, obesity, and the combination of hypertension and dyslipidemia. [Fig 2](#pone.0201308.g002){ref-type="fig"} shows the HRs of PCa and P for interaction in each subgroup after controlling for age, smoking status, alcohol consumption, physical exercise, and yearly income.

![The impact of on the risk nonalcoholic fatty liver disease of prostate cancer in different subgroups.\
Forrest plots of hazard ratios (HR) and 95% confidential interval (CI) adjusted for age, smoking, drinking, regular exercise, income according to subgroups were illustrated. Fatty liver index (a) or hepatic steatosis index (b) was used to define the nonalcoholic fatty liver disease.](pone.0201308.g002){#pone.0201308.g002}

In terms of the FLI, subjects aged 65 years or older showed the highest risk for PCa compared to other age groups (HR 1.04; 95% CI 1.00--1.07, P ~interaction~ \< 0.001) ([Fig 2A](#pone.0201308.g002){ref-type="fig"}). Current alcohol consumers (\< 30 g/day for men) or non/ex-smokers and were more closely associated with developing PCa. The associations between the FLI and developing PCa were more prominent in normotensive, nondyslipidemic and normoglycemic persons than those with ≥ 1 of above three disorders (HR 1.07; 95% CI 1.01--1.13 vs. HR 1.01; 95% CI 0.98--1.04, P ~interaction~ = 0.028). Each DM, obesity and abdominal obesity had a similar trend, but they did not show significant differences.

Regarding the interaction between the HSI and developing PCa, the HSI had similar results as the FLI ([Fig 2B](#pone.0201308.g002){ref-type="fig"}). That is, persons aged ≥ 40 years old, those who were not currently smoking or smoked in the past, those who currently consumed alcohol (\< 30 g/day), and those without hypertension, dyslipidemia, and diabetes had a closer association of developing PCa than each counterpart. Non-obese persons with NAFLD defined by HSI had a higher risk of developing PCa than obese persons with NAFLD defined by HSI (HR 1.05; 95% CI 1.00--1.10 vs. HR 1.04; 95% CI 1.01--1.08, P ~interaction~ = 0.069).

Discussion {#sec017}
==========

In the present study, we found that NAFLD defined by the FLI or HSI was associated with the development of PCa after controlling for age and other confounding factors. The risk of developing PCa is consistently higher with an FLI ≥ 13.7, and it steadily increased as the HSI increased ≥ 29.1. Moreover, the positive association was more prominent in persons who were older, non-current smoking, non-obese, consumed alcohol or did have none of the dyslipidemia, hypertension, or diabetes, which account for metabolic syndrome.

According to Korean cohort studies, the mean age at diagnosis of NAFLD and PCa was 41.6 and 68.7 years old, respectively \[[@pone.0201308.ref012], [@pone.0201308.ref022]\]. This discrepancy in affected ages can lead to confounding. The incidence rate of PCa is the highest in 50--60's where that of NAFLD is decreasing. As a result, the incidence rates of PCa in NAFLD patients (by FLI \> 60 or HSI \> 36) during this range of age were lower than those in the non-NAFLD. However, after controlling the age, the hazard ratio of PCa in the NAFLD group is higher than that in the non-NAFLD group ([Table 2](#pone.0201308.t002){ref-type="table"}). These results remain consistent after controlling several covariates besides age.

To date, only two studies have specifically investigated the association between NAFLD and PCa. In the study that compared the development of malignancies in subjects with NAFLD diagnosed by US and matched hepatitis C virus-infected patients, PCa developed in 12.6% and 3.5% in each group, respectively \[[@pone.0201308.ref010]\]. The other study reported that NAFLD was a protective factor against recurrence after radical prostatectomy because the NAFLD group showed a significantly longer time-to-recurrence than patients without NAFLD \[[@pone.0201308.ref011]\]. Colorectal cancer and pancreatic, breast, and renal cancer have been consistently reported as being associated with NAFLD \[[@pone.0201308.ref007], [@pone.0201308.ref023], [@pone.0201308.ref024]\]. Given that PCa has been regarded as a metabolic syndrome-associated cancer along with colorectal, pancreatic, and breast cancer \[[@pone.0201308.ref007]\], there is a high possibility that PCa may be associated with NAFLD, too.

The mechanisms underlying the association between NAFLD and the excess risk of PCa are not fully elucidated. The most alleged mechanism linking NAFLD and PCa is the alteration of insulin and insulin-like growth factor-I (IGF-1) similar to other cnacers \[[@pone.0201308.ref025]\]. It has been reported that elevated serum levels of IGF-1 were associated with PCa \[[@pone.0201308.ref026], [@pone.0201308.ref027]\].

Gender-specific manifestations of NAFLD have been consistently reported \[[@pone.0201308.ref028]\]. Most studies found NAFLD to be more prevalent in men \[[@pone.0201308.ref029], [@pone.0201308.ref030]\] and some studies identified different risk factors for the development of NAFLD by gender \[[@pone.0201308.ref031]\]. Moreover, the reproductive status also critically affects the risk of development and progression of this disease \[[@pone.0201308.ref032]\]. This sexual dimorphism supports a close link between endocrine derangements and the pathogenesis of NAFLD. For example, testosterone deficiency accompanied by an increased accumulation of visceral adipose tissue and insulin resistance has been observed. The lower levels of total testosterone were associated with the development of NAFLD \[[@pone.0201308.ref033], [@pone.0201308.ref034]\] and PCa \[[@pone.0201308.ref035], [@pone.0201308.ref036]\]. Besides, metabolic syndrome and NAFLD aggravated the severity of prostatic inflammation which could promote uncontrolled proliferation \[[@pone.0201308.ref037]\]. This hormonal basis underlying NAFLD may be the reason for the observed more prominent association with older men whose testosterone is physiologically reducing.

Interestingly, the positive associations between the NAFLD defined by HSI and developing PCa were more prominent in non-obese persons than in obese persons. The HR for PCa in NAFLD defined by FLI or HSI was also higher in the normotensive, non-dyslipidemic, and non-diabetic persons than that in individuals presenting any of them. Considering the higher prevalence of obesity or metabolic syndrome in NAFLD patients compared with healthy individuals, the stronger association between the NAFLD and the development of PCa in non-obese or persons with null-metabolic syndrome components is an unexpected result. Similar to this, a stronger association of NAFLD with the metabolic syndrome in lean individuals than in obese individuals has been previously observed \[[@pone.0201308.ref038], [@pone.0201308.ref039]\]. This might come from the diluting the powerful impact of obesity or DM on the development of PCa by dividing the population by the presence or absence of DM or obesity. This also partially reflects that BMI fails to assess the visceral fat distribution \[[@pone.0201308.ref040]\]. A different mechanism may underlie developing PCa in a different population, and this needs further studies.

Nonetheless, it is of note that NAFLD particularly based on HSI, could predict PCa even in the normal range of BMI. While most persons with NAFLD have insulin resistance, only a minority of them exhibit the full-blown metabolic syndrome, suggesting that NAFLD may precede the obesity or DM \[[@pone.0201308.ref038]\]. Indeed, it has been reported that 10% to 30% of non-obese individuals have evidence of NAFLD \[[@pone.0201308.ref039]\]. NAFLD may independently predict insulin resistance, identifying individuals who can be missed by criteria of metabolic syndrome \[[@pone.0201308.ref038]\].

The strength of our study is that it was a nationwide population-based study. While obesity has been inconsistently linked to the risk of PCa, so far \[[@pone.0201308.ref041]\], this study showed that FLI and HSI as well as each of obesity, dyslipidemia, abdominal obesity and DM had a positive association with an increased risk of PCa ([Table 3](#pone.0201308.t003){ref-type="table"}).

One of the significant limitations of this study is that imaging modality was not used for diagnosis of NAFLD.

FLI is a proxy for ultrasonography and does not accurately quantify steatosis \[[@pone.0201308.ref042]\]. Semi-quantitative indices using US could diagnose with NAFLD by providing additional information on metabolic derangements and histological changes \[[@pone.0201308.ref043]--[@pone.0201308.ref045]\]. Other limitations include the possible misclassification of individuals who may have viral hepatitis B or C or asymptomatic compensated cirrhosis into the NAFLD group. The family history of PCa did not adjust multivariate analyses due to a lack of a family history for the specific cancer. Nevertheless, the increasing prevalence of metabolic syndrome worldwide and the high incidence of some malignancies, including PCa, support the possible association between NAFLD and the development of some cancers. Additional studies are warranted to ascertain the risk of PCa in NAFLD using semi-quantitative ultrasonographic indices and exclusion of competing causes of liver disease.
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